Novo’s Victoza, new indication to reduce CV risk

Novo Nordisk announced that the FDA approved a new indication for Victoza (liraglutide) to reduce the risk of major cardiovascular events in adults with type 2 diabetes and cardiovascular disease. The indication is based on the results from the LEADER trial, which demonstrated that Victoza statistically significantly reduced (-13%) the risk of cardiovascular death, heart attack or non-fatal stroke vs placebo, when added to standard of care.
(Source Novo Nordisk)